New England Journal of Medicine , 387 (3), 205-216
The research outcomes suggest that human cardiac cells treatment with tirzepatide resulted in an augmentation of Sarco/Endoplasmic Reticulum Calcium ATPase 2 (SERCA2) and p-Phospholamban (p-PLN) activity and expression while reducing Calcium/Calmodulin-Dependent ProtienKinase II (CAMKII) expression
The advancement of dual and multi-receptor agonists, such as tirzepatide, signifies the most recent progression in this therapeutic category, demonstrating enhanced effectiveness in metabolic regulation and weight control
Overdosage Signs of an overdose of Abilify may include throwing up, restlessness, impaired awareness, and irregular heart rate
Some individuals may experience mild, temporary symptoms such as stomach upset or changes in bowel habits